Emerging drugs for the treatment of gastrointestinal stromal tumour

Area of Science:

• Oncology
• Gastrointestinal Oncology
• Drug Discovery

Background:

• Tyrosine kinase inhibitors (TKIs) have revolutionized gastrointestinal stromal tumor (GIST) treatment.
• Therapeutic resistance to approved TKIs presents a significant clinical challenge.
• There is a critical need for novel treatment strategies in GIST.

Purpose of the Study:

• To review emerging drugs and therapeutic approaches for GIST.
• To identify novel inhibitors targeting KIT and PDGFRA receptors and downstream pathways.
• To explore potential new targets and drug classes for GIST treatment.

Main Methods:

• Extensive literature search of PUBMED database.
• Identification of early-phase clinical trial data for GIST therapeutics.
• Analysis of ongoing research on novel inhibitors and drug classes.

Main Results:

• Multiple novel therapeutic agents are under investigation for GIST.
• Emerging drugs target KIT/PDGFRA receptors, downstream pathways (mTOR, PIK3), and other targets (ETV1/MEK, MET, FGFR, IGF1R).
• Investigational agents include histone deacetylase, heat shock protein 90, and cyclin-dependent kinase inhibitors, alongside immune checkpoint inhibitors.

Conclusions:

• Agents effective against imatinib-resistant mutations or refractory GIST are most likely for development.
• The role of immunotherapy in GIST treatment remains under investigation.
• Continued research into novel therapeutic strategies is crucial for overcoming TKI resistance in GIST.